50 results on '"Siemers, Eric R"'
Search Results
2. Eligibility in the INTERCEPT‐AD trial: visual amyloid classification for equivocal SUVrs in early Alzheimer’s disease
3. Baseline characteristics of INTERCEPT‐AD: A phase 1 trial with ACU193 targeting soluble amyloid beta oligomers for the treatment of early Alzheimer’s disease
4. Expectations and clinical meaningfulness of randomized controlled trials
5. Evidence that semaphorin 4D is upregulated in neurons in Huntington’s and Alzheimer’s diseases: Effects of a SEMA4D blocking antibody on FDG‐PET in a clinical trial, and treatment rationale for its use in AD
6. IC‐P‐216: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION‐3 TRIAL
7. O3‐13‐02: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION‐3 TRIAL
8. National Institute on Aging - Alzheimer's Association Research Framework lays the groundwork for deeper understanding of Alzheimer's disease
9. [P1-049]: SOLANEZUMAB CENTRAL TARGET ENGAGEMENT AND PHARMACODYNAMIC ACTIVITY IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD: COMPARISON TO EXPEDITION/EXPEDITION 2
10. THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS): FINDINGS FROM THE EXPEDITION3 TRIAL
11. [P2-002]: EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGENERATION IN THE EXPEDITION3 TRIAL IN MILD ALZHEIMER DISEASE
12. [P1-042]: PLASMA PHARMACOKINETICS AND PHARMACODYNAMICS OF SOLANEZUMAB IN MILD AND MODERATE AD PATIENTS
13. THE PATIENT VOICE: EXPLORING TREATMENT PREFERENCES IN PARTICIPANTS WITH MILD COGNITIVE CONCERNS TO INFORM REGULATORY DECISION MAKING
14. [IC-P-042]: COMPARISON OF BASELINE ARIA-H PREVALENCE AT 1.5T AND 3T MRI FIELD STRENGTHS IN A MULTI-SITE GLOBAL CLINICAL TRIAL WITH A COHORT OF 2,137 AD SUBJECTS
15. [P4-017]: DELAYED-START ANALYSES IN THE PHASE 3 SOLANEZUMAB EXPEDITION3 STUDY IN MILD ALZHEIMER's DISEASE
16. [P1-394]: COMPARISON OF BASELINE ARIA-H PREVALENCE AT 1.5T AND 3T MRI FIELD STRENGTHS IN A MULTI-SITE GLOBAL CLINICAL TRIAL WITH COHORT OF 2137 AD SUBJECTS
17. [IC-P-043]: EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGENERATION IN THE EXPEDITION3 TRIAL IN MILD ALZHEIMER DISEASE
18. [P1-044]: SAFETY OF SOLANEZUMAB IN PHASE 3 STUDIES IN INDIVIDUALS WITH MILD ALZHEIMER's DISEASE DEMENTIA
19. [FTS3–02–01]: 2017 NIA‐AA RESEARCH FRAMEWORK TO INVESTIGATE THE ALZHEIMER's DISEASE CONTINUUM
20. PET BIOMARKERS IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD
21. [P4–155]: DERIVING A CUT‐OFF FOR THE ELECSYS® β‐AMYLOID (1–42) IMMUNOASSAY FOR USE IN CLINICAL TRIALS SUPPORTED BY ELI LILLY FOR PATIENTS WITH CLINICALLY DEFINED ALZHEIMER's DISEASE (AD)
22. Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials
23. P2-007: Exposure-Adjusted Analysis of Treatment-Emergent Adverse Events from Expedition and Expedition2 Trials of Solanezumab for The Treatment of Alzheimer’s Disease
24. P4-127: Exploring the Utility of CSF Neurogranin Levels in An Alzheimer’s Disease Clinical Trial
25. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
26. IC-P-030: Comparison of reference regions for improved detection of change in florbetapir PET from phase 3 solanezumab trials
27. P3‐285: Safety of solanezumab in the expedition‐ext study up to 2 years in a mild to moderate Alzheimer's disease population
28. P1‐119: Prospective quality‐control monitoring in the context of a clinical trial
29. O3-01-04: Comparison of reference regions for improved detection of change in florbetapir PET from phase 3 solanezumab trials
30. F4-03-02: Delayed-start analyses of up to 3.5 years in the phase 3 solanezumab expedition program in mild Alzheimer's disease
31. Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
32. Improving Alzheimer's disease phase II clinical trials
33. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease
34. Screening and treatment for Alzheimer's disease: Predicting population‐level outcomes
35. Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies
36. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
37. Revision of the criteria for Alzheimer's disease: A symposium
38. Safety profile of Alzheimer's disease patient populations over 18 months using ADNI and controlled clinical trial data
39. P3-176: Optimal combination of biomarkers for predicting MCI to AD conversion selected using a bayesian framework
40. Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study
41. O4-04-02: Identification, characterization, and comparison of amino-terminally truncated Aβ 42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment
42. P1-275: Measurement of cerebrospinal fluid total tau and phospho-tau in phase 2 trials of therapies targeting Aβ
43. P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease
44. Commentary on “A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium”
45. Partnership between academia and industry for drug discovery in Alzheimer's disease
46. P4–246: Passive immunotherapy with M266 results in altered CSF Aβ
47. O4-03-04: Safety assessments and biomarker changes following a monoclonal Aβ antibody given to subjects with Alzheimer's disease
48. P4-312: A model-based comparison of the nonclinical and clinical effects of anti-Aβ antibodies on plasma Aβ1-40 levels
49. Commentary on “Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease”
50. Role of biomarkers in studies of presymptomatic Alzheimer's disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.